These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 6871877)

  • 1. Age dependence of the early-phase pharmacokinetics of doxorubicin.
    Robert J; Hoerni B
    Cancer Res; 1983 Sep; 43(9):4467-9. PubMed ID: 6871877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetic study of doxorubicin in the treatment of malignant non-Hodgkin's lymphomas].
    Robert J; Vrignaud P; Iliadis A; Eghbali H; Hoerni B
    Nouv Rev Fr Hematol (1978); 1983; 25(2):91-5. PubMed ID: 6866757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours.
    Thomson AH; Vasey PA; Murray LS; Cassidy J; Fraier D; Frigerio E; Twelves C
    Br J Cancer; 1999 Sep; 81(1):99-107. PubMed ID: 10487619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration.
    Busse D; Würthwein G; Hinske C; Hempel G; Fromm MF; Eichelbaum M; Kroemer HK; Busch FW
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Sep; 366(3):218-25. PubMed ID: 12172704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of age on the early disposition of doxorubicin.
    Li J; Gwilt PR
    Cancer Chemother Pharmacol; 2003 May; 51(5):395-402. PubMed ID: 12679882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin.
    Gabizon A; Isacson R; Rosengarten O; Tzemach D; Shmeeda H; Sapir R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):695-702. PubMed ID: 17549475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
    Giordano SH; Booser DJ; Murray JL; Ibrahim NK; Rahman ZU; Valero V; Theriault RL; Rosales MF; Rivera E; Frye D; Ewer M; Ordonez NG; Buzdar AU; Hortobagyi GN
    Clin Cancer Res; 2002 Nov; 8(11):3360-8. PubMed ID: 12429622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors.
    Fujisaka Y; Horiike A; Shimizu T; Yamamoto N; Yamada Y; Tamura T
    Jpn J Clin Oncol; 2006 Dec; 36(12):768-74. PubMed ID: 17095524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome.
    Ibrahim NK; Frye DK; Buzdar AU; Walters RS; Hortobagyi GN
    Arch Intern Med; 1996 Apr; 156(8):882-8. PubMed ID: 8774207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.
    Holmes FA
    Semin Oncol; 1995 Aug; 22(4 Suppl 8):9-15. PubMed ID: 7543702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical and pharmacokinetic study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762).
    Vasey PA; Bissett D; Strolin-Benedetti M; Poggesi I; Breda M; Adams L; Wilson P; Pacciarini MA; Kaye SB; Cassidy J
    Cancer Res; 1995 May; 55(10):2090-6. PubMed ID: 7743508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of TLK1B in elevation and recurrence in doxorubicin-treated breast cancer patients with high eIF4E overexpression.
    Byrnes KW; DeBenedetti A; Holm NT; Luke J; Nunez J; Chu QD; Meschonat C; Abreo F; Johnson LW; Li BD
    J Am Coll Surg; 2007 May; 204(5):925-33; discussion 933-4. PubMed ID: 17481512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy.
    Piazza E; Donelli MG; Broggini M; Sessa C; Natale N; Ottolenghi L; Marsoni S; Libretti A; Mangioni C; Morasca L
    Cancer Treat Rep; 1980; 64(8-9):845-54. PubMed ID: 7448822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies.
    Rubin EH; de Alwis DP; Pouliquen I; Green L; Marder P; Lin Y; Musanti R; Grospe SL; Smith SL; Toppmeyer DL; Much J; Kane M; Chaudhary A; Jordan C; Burgess M; Slapak CA
    Clin Cancer Res; 2002 Dec; 8(12):3710-7. PubMed ID: 12473580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
    Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
    Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer.
    Biganzoli L; Coleman R; Minisini A; Hamilton A; Aapro M; Therasse P; Mottino G; Bogaerts J; Piccart M
    Crit Rev Oncol Hematol; 2007 Jan; 61(1):84-9. PubMed ID: 17116400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.
    Mross K; Niemann B; Massing U; Drevs J; Unger C; Bhamra R; Swenson CE
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):514-24. PubMed ID: 15322827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL; Tseng YL
    Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: a phase I/II trial.
    Kouloulias VE; Dardoufas CE; Kouvaris JR; Gennatas CS; Polyzos AK; Gogas HJ; Sandilos PH; Uzunoglu NK; Malas EG; Vlahos LJ
    Clin Cancer Res; 2002 Feb; 8(2):374-82. PubMed ID: 11839652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.